Antares Pharma, Inc. (ATRS)

[H2R]

Not too shabby :) up > 9%!

Antares Pharma beats by $0.01, beats on revenue
Antares Pharma (NASDAQ:ATRS): Q1 GAAP EPS of -$0.03 beats by $0.01.
Revenue of $23.29M (+93.0% Y/Y) beats by $5.12M.

Shares +0.36% PM.

“The record revenue we reported today marks the start of what we believe will be an extraordinary year for Antares. We believe the significant growth in revenue validates our strategy to focus on the development of both propriety and partnered products.” said Robert F. Apple, President and Chief Executive Officer of the Company. “This strategy provided six commercial products currently on the market, all contributing to our top-line growth. Our four partnered products with Teva, AMAG and Ferring leverages their commercial experience and infrastructure which allows us to solely focus on the success of XYOSTED and OTREXUP. The XYOSTED launch is off to a strong start with month over month prescription growth since launch. Over time, we believe that revenue from XYOSTED will increase and become a significant contributor to our expanding and diversified commercial business.”

What we believe will be an extraordinary year for Antares: how often does one see such a statement from a CEO?

Best of luck with your investments!